Earnings Call · Q2 FY2022·2022-08-03

Q2 22EPS +33.88%·Rev n/aQ1 22EPS -17.65%·Rev n/aQ4 21EPS 0.00%·Rev n/aQ3 21EPS -20.00%·Rev n/a⚠ consensus missing

RIGEL PHARMACEUTICALS INC RIGL

Dolly Vance — Investor Relations or similar (host of financial results call)

Raul Rodriguez — Chief Executive Officer

Dave Santos — Chief Commercial Officer

Jorge Cortes — Director of the Georgia Cancer Center

Wolfgang Dummer — Chief Medical Officer

Dean Schorno — Chief Financial Officer

+8.5%1d on move date+6.9% vs SPY3d+16.9%5d+4.6%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RIGL calls or request research access.

More RIGL calls Browse calls Request research access